Vertex Pharmaceuticals Incorporated (VRTX) Position Lifted by Oppenheimer Asset Management Inc.

Oppenheimer Asset Management Inc. lifted its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 78.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 25,745 shares of the pharmaceutical company’s stock after purchasing an additional 11,282 shares during the period. Oppenheimer Asset Management Inc.’s holdings in Vertex Pharmaceuticals were worth $3,913,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. First Republic Investment Management Inc. lifted its position in shares of Vertex Pharmaceuticals by 2.8% during the third quarter. First Republic Investment Management Inc. now owns 12,643 shares of the pharmaceutical company’s stock valued at $1,922,000 after purchasing an additional 346 shares in the last quarter. Magnetar Financial LLC bought a new position in shares of Vertex Pharmaceuticals during the third quarter valued at about $488,000. Asset Management One Co. Ltd. lifted its position in shares of Vertex Pharmaceuticals by 2.1% during the third quarter. Asset Management One Co. Ltd. now owns 391,213 shares of the pharmaceutical company’s stock valued at $59,434,000 after purchasing an additional 7,896 shares in the last quarter. AMP Capital Investors Ltd lifted its position in shares of Vertex Pharmaceuticals by 24.2% during the third quarter. AMP Capital Investors Ltd now owns 130,142 shares of the pharmaceutical company’s stock valued at $19,788,000 after purchasing an additional 25,378 shares in the last quarter. Finally, Crawford Lake Capital Management LLC bought a new position in shares of Vertex Pharmaceuticals during the third quarter valued at about $17,644,000. 93.33% of the stock is currently owned by institutional investors.

A number of research analysts recently weighed in on VRTX shares. Zacks Investment Research lowered shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, October 24th. Vetr lowered shares of Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $181.00 price objective on the stock. in a research report on Monday, September 4th. Royal Bank Of Canada lifted their price objective on shares of Vertex Pharmaceuticals from $175.00 to $181.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 18th. HC Wainwright reaffirmed a “hold” rating and issued a $85.00 price objective on shares of Vertex Pharmaceuticals in a research report on Thursday, October 26th. Finally, Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $205.00 price objective on shares of Vertex Pharmaceuticals in a research report on Thursday, October 26th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty-three have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $173.15.

In other news, EVP Stuart A. Arbuckle sold 221 shares of Vertex Pharmaceuticals stock in a transaction dated Wednesday, November 15th. The shares were sold at an average price of $147.29, for a total value of $32,551.09. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Ian F. Smith sold 2,125 shares of Vertex Pharmaceuticals stock in a transaction dated Monday, October 16th. The stock was sold at an average price of $155.61, for a total transaction of $330,671.25. Following the completion of the transaction, the chief operating officer now owns 118,013 shares of the company’s stock, valued at approximately $18,364,002.93. The disclosure for this sale can be found here. Insiders sold 218,519 shares of company stock valued at $31,819,910 in the last quarter. Corporate insiders own 1.80% of the company’s stock.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) opened at $143.61 on Friday. The firm has a market cap of $35,097.85, a PE ratio of 231.30, a PEG ratio of 3.32 and a beta of 1.58. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.28 and a quick ratio of 3.14. Vertex Pharmaceuticals Incorporated has a 12 month low of $71.46 and a 12 month high of $167.85.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Wednesday, October 25th. The pharmaceutical company reported $0.53 earnings per share for the quarter, topping the consensus estimate of $0.04 by $0.49. The firm had revenue of $578.20 million during the quarter, compared to the consensus estimate of $522.07 million. Vertex Pharmaceuticals had a net margin of 8.53% and a return on equity of 9.23%. The company’s revenue was up 39.7% on a year-over-year basis. During the same quarter last year, the company earned $0.16 earnings per share. equities research analysts expect that Vertex Pharmaceuticals Incorporated will post 0.76 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Vertex Pharmaceuticals Incorporated (VRTX) Position Lifted by Oppenheimer Asset Management Inc.” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another site, it was copied illegally and reposted in violation of United States & international trademark and copyright law. The correct version of this article can be read at https://www.dispatchtribunal.com/2017/12/10/vertex-pharmaceuticals-incorporated-vrtx-position-lifted-by-oppenheimer-asset-management-inc.html.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply